AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Inteliquet Signs Cooperative R&D Agreement (CRADA) with the National Cancer Institute

May 20, 2019

MEMPHIS, Tenn.--(BUSINESS WIRE)--May 20, 2019--

Inteliquet, a leading provider of intelligent technology, insights and services for clinical trials, research, and translational medicine is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Health and Human Services, as represented by the National Cancer Institute (NCI). The principal goal of this research agreement is to develop a clinic-ready, web-based tool, using NCI’s Oncogenomics browser with Inteliquet’s proprietary Precision Medicine Platform to aid clinicians in therapeutic decision-making.

“This CRADA will combine the scientific and software-based data automation expertise of the NCI and Inteliquet, respectively, to develop a bioinformatics platform that provides clinicians and scientists with user-friendly access to data and analyses relating to genetic mutations and treatment options,” said Carla Balch, CEO of Inteliquet.

One of the predominant fields of oncology research focuses on genetic causes and treatments of cancer, and detailed integrated genomic analyses of germline and tumor material has paved the way for precision genome-guided medicine targeting actionable mutations. NCI has developed a web-based tool to flag these actionable mutations, and through the CRADA with Inteliquet, will leverage the latter’s Precision Medicine Platform to address the need to rapidly integrate clinical and molecular data, linking genetic variants to drugs, status of FDA approval and clinical trials. The bioinformatics platform that is developed will take genetic and genomic data as an input, process the actionable variants, and present the findings to end-users in a user-friendly web browser while capturing patients’ outcomes.

The Principal Investigators under the CRADA are Jeremy Miller, Ph.D., Chief Technology Officer at Inteliquet and Javed Khan, M.D., Deputy Chief, Genetics Branch at the National Cancer Institute.

About Inteliquet

Inteliquet is a leading provider of intelligent technology, insights and expertise that help dramatically to reduce the barriers and time involved in designing and conducting clinical trials and research, from feasibility and site selection to patient screening and matching. We harness vast sets of oncology and patient data to bring a new level of clarity to the process and to accelerate new scientific discoveries. Our team, partners, customers, and Scientific Advisory Board are passionate about ensuring that every patient—regardless of race, geography, age, sex, economic status, or stage of disease—has access to promising therapies as soon as they become available to help improve the care they, and future generations, receive. Find out more at www.inteliquet.com, and follow us on Twitter, LinkedIn and Facebook.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005233/en/

CONTACT: Dorit Baxter, Senior Vice President of Marketing

Inteliquet

(401) 871-0734

dbaxter@inteliquet.com

KEYWORD: UNITED STATES NORTH AMERICA TENNESSEE

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT INTERNET SOFTWARE HEALTH CLINICAL TRIALS GENETICS ONCOLOGY RESEARCH FDA SCIENCE

SOURCE: Inteliquet

Copyright Business Wire 2019.

PUB: 05/20/2019 06:00 AM/DISC: 05/20/2019 06:01 AM

http://www.businesswire.com/news/home/20190520005233/en

All contents © copyright 2019 The Associated Press. All rights reserved.